Coherus BioSciences Reports Q3 Non-GAAP EPS Beat Amid Revenue Miss
Coherus BioSciences (CHRS) reported third-quarter financial results featuring a slight beat on the earnings side, with Non-GAAP EPS of -$0.20, exceeding expectations by $0.01. However, the company missed revenue estimates, reporting $14.27 million against an expected higher figure, representing a miss of $1.66 million despite a 23.3% year-over-year increase in revenue. Following the announcement, shares experienced a decline of approximately 2%. Alongside the financial results, the company highlighted promising early-stage clinical data regarding its drug candidate tagmokitug for the treatment of esophageal cancer.
Tickers: $CHRS
Topics: clinical trial data earnings report EPS beat revenue miss